23,254 Shares in Supernus Pharmaceuticals, Inc. $SUPN Purchased by Jupiter Topco LLC

Jupiter Topco LLC bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 23,254 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,082,000.

Several other large investors have also recently bought and sold shares of SUPN. Royal Bank of Canada raised its position in shares of Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after buying an additional 4,729 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 35.2% in the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after acquiring an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Supernus Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock valued at $978,000 after acquiring an additional 1,297 shares during the period. Millennium Management LLC raised its holdings in Supernus Pharmaceuticals by 370.5% during the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after purchasing an additional 112,886 shares in the last quarter. Finally, Empowered Funds LLC raised its holdings in Supernus Pharmaceuticals by 16.0% during the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after purchasing an additional 6,619 shares in the last quarter.

Supernus Pharmaceuticals Stock Down 1.0%

SUPN opened at $43.53 on Friday. The firm has a market cap of $2.53 billion, a PE ratio of -22.67, a P/E/G ratio of 0.80 and a beta of 0.56. The business has a fifty day simple moving average of $46.69 and a 200-day simple moving average of $48.41. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $42.45 and a fifty-two week high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The company had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. During the same quarter in the previous year, the firm earned $0.40 earnings per share. The business’s revenue was up 32.4% compared to the same quarter last year. On average, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $62.83.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.